· 5 min read
Can Your Operator Survive Real Scrutiny? What a Courtroom Taught Me
Every healthtech company gets cross-examined eventually. What defending a damages model in court taught me about operators who hold up under pressure.
Short answer. An operator holds up under scrutiny by understanding the material well enough that pressure doesn’t change the answer: knowing the science behind the summary, knowing which assumptions the numbers depend on, and separating what is measured from what is estimated. In healthtech, that scrutiny comes from investors, health systems, clinicians, and regulators.
Every healthtech company gets cross-examined eventually, usually far from a courtroom.
It happens when an investor’s analyst asks how a number was built. It happens when a health system’s security team sends back a questionnaire your sales deck doesn’t answer, or when a clinical reviewer asks what your outcome claim was measured against. Someone on your side has to answer, under pressure, with the founder possibly not in the room.
Founders worry about this when they hire an operator, and they should. The person running operations will sit across the table from skeptics. If that person folds, the company looks like it doesn’t know its own business.
My most useful lesson on this came from an actual courtroom.
The Greenleaf story
In 1993, at Greenleaf Medical Systems, I was asked to evaluate a virtual reality technology against the performance terms of an exclusive contract the company held for medical use.
The job had two halves. The first was technical: had the technology performed as the contract required? The second was financial: if it hadn’t, what were the damages? I built both the technical assessment and the damages model, and then I defended both in court.
The surprise was how much of the model survived cross-examination, and how little of it depended on being clever.
What held up, and why
Composure under that kind of scrutiny is not a personality trait. It comes from understanding the material well enough that pressure doesn’t change your answer.
Three things made the difference, and they apply to any operator facing diligence today.
1. Knowing the science behind the summary
I could answer the technical questions because I had done the evaluation myself. An operator who only knows the slide version of your product will defer every hard question to the founder or the engineering lead. In a diligence meeting, every deferral reads as a gap.
2. Knowing what the numbers depend on
A model is only as strong as the assumption underneath it. The questions that matter in cross-examination go after the inputs: where did this figure come from, and what happens if it’s wrong? If the assumptions are written down and sourced, the answer is calm. If they live in one person’s head, the answer changes under pressure.
3. Separating what you know from what you estimated
The fastest way to lose a room is to defend an estimate as if it were a fact. Saying “this is measured, this is estimated, and here is how we estimated it” is a stronger position than a confident number that falls apart on the second question.
Why this matters more in healthtech
In most industries, scrutiny comes from customers and investors. In healthtech it also comes from clinicians, compliance teams, payers, and regulators, and each of them asks a different kind of question. The operator has to follow a clinical argument and a financial one in the same meeting.
That is where an operator who understands the science earns the seat. Someone who has to learn your industry on the job can learn the vocabulary quickly. Holding a position under cross-examination takes longer.
How to test an operator before you hire one
Three questions will tell you most of what a courtroom would.
| Ask | What a strong answer sounds like |
|---|---|
| Walk me through a decision you defended to a skeptic. | A specific room, a specific challenge, and what they said back |
| What did your last financial model depend on most? | One named assumption, where it came from, and what happened when it moved |
| Push back on their answer once. | The answer gets more specific, not different |
If the answer to the third one changes, you have learned what you needed to know.
Check yours
Who on your team would answer an investor’s hardest question if you were not in the room? If the honest answer is nobody, close that gap before the next round starts.
I trained as a bioengineer (MSE and BSE at Penn), earned an MBA at Wharton, and spent more than twenty years in health IT, medical devices, and executive operations. I have been through FDA clearance work; I have not run a submission myself.
If you would like to see where your operations would hold up under scrutiny, a diagnostic conversation is the next step. Thirty minutes. No charge. You leave with a specific recommendation, even if it’s not me. Start there.
Alden Levy is the founder of Engine No. 9, a fractional COO practice for healthtech and medtech founders from Seed through Series B. He trained as a bioengineer at the University of Pennsylvania and holds an MBA from Wharton.